Quantcast

Latest Sirolimus Stories

2014-09-16 08:29:53

-- Differentiated Design Yields Excellent Tissue Healing and Sustained Safety Profile -- DURHAM, N.C., Sept. 16, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that three-year clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®)) were presented at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference being held in Washington, D.C., September 13-17....

autism neurons
2014-08-25 03:30:54

Karin Eskenazi, Columbia University Medical Center May be possible to prune synapses with drug after diagnosis Children and adolescents with autism have a surplus of synapses in the brain, and this excess is due to a slowdown in a normal brain “pruning” process during development, according to a study by neuroscientists at Columbia University Medical Center (CUMC). Because synapses are the points where neurons connect and communicate with each other, the excessive synapses may have...

2014-08-04 13:00:53

Cancer Research UK Cancer Research UK scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumor and stops it spreading, according to research published in Gut. "It's a crucial step forward in developing new treatments for this devastating disease..." - Dr Jennifer Morton, study author The scientists, at the Cancer Research UK Beatson Institute and the University of Glasgow, treated mice with pancreatic cancers caused by...

2014-07-09 08:28:18

-- Newly Issued US Patent Covers Medical Device Coating Process and Compositions -- DURHAM, N.C., July 9, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical devices with precise drug-delivery coatings. These technologies currently are used in producing the company's drug-eluting stent system, MiStent SES(®). The...

2014-06-03 16:25:04

HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S. commercialization of Envarsus(®) XR (tacrolimus extended-release tablets) an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients. Key points: -- Envarsus( )XR is an extended release formulation of tacrolimus being designed for once-daily...

2014-05-23 08:23:56

-- Sustained Safety Profile -- DURHAM, N.C., May 23, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. Presentations by principal investigator William Wijns, M.D., Ph.D. of the Cardiovascular Center in Aalst, Belgium, highlighted results of long-term clinical follow-up of the MiStent Sirolimus Eluting Absorbable Polymer Coronary...

2014-05-23 04:20:45

COMBO(TM) Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 /PRNewswire/ -- OrbusNeich today announced long-term results from its REMEDEE Trial. In addition to showing that the COMBO(TM) Dual Therapy Stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing. Key findings include: -...

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-05-15 16:28:10

-- Oral Presentations to Include New Long-Term Results from First-in-Human Study -- DURHAM, N.C., May 15, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced the updated three- and two-year clinical outcomes from its DESSOLVE I and II clinical trials, respectively, will be presented at the EuroPCR conference to be held in Paris, France from May 20 - 23. Two oral presentations will be made by William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium: -- DESSOLVE II...

2014-04-28 23:04:36

Findings Show Several FDA-Approved Drugs May also be Effective in Patients Diagnosed with Dilated Cardiomyopathy New York, NY (PRWEB) April 28, 2014 Scientists at Icahn School of Medicine at Mount Sinai, along with collaborators at institutions in India, Italy, and Japan, have identified the first gene linked to childhood-onset familial dilated cardiomyopathy (DCM), one of the most common heart muscle diseases in children. It is a progressive and potentially fatal heart condition...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'